EHR

Boehringer and Click Therapeutics present pivotal data for investigational prescription digital therapeutic CT-155 showing a statistically significant reduction in negative symptoms of schizophrenia

Addison Care Debuts at athenahealth 2025 Thrive Conference: 3D Virtual Caregiver Tackles Global Healthcare Crisis of Non-Adherence and Workforce Shortages

LAS CRUCES, NEW MEXICO / ACCESS Newswire / October 9, 2025 / The healthcare industry is approaching a breaking point....

AHIMA 2025: The 20 Must-See Exhibitors With Top User Scores and Future-Focused HIM Innovations Identified by Black Book Surveys

Highlighting the Solutions Transforming Data Accuracy, Automation, and AI-Driven Revenue Integrity at the Minneapolis Convention Center, October 12–14, 2025 MINNEAPOLIS,...

Healthcare Triangle Takes Bold Step toward AI-Driven Future with the Signing of a Non-Binding LOI for the Acquisition of Teyame.AI, which is on track to generate $34M in Revenue for fiscal year 2025 and would create for Healthcare Triangle a Next-Generation Global Customer Engagement Platform

U.S. FDA approves Boehringer’s JASCAYD® (nerandomilast tablets) as first new treatment option for adults with IPF in over a decade

Ingelheim, Germany/Ridgefield, Connecticut, U.S. Idiopathic pulmonary fibrosis (IPF) is a progressive disease, causing a continuous decline in lung function.1Approval is...

error: Content is protected !!